Details for Patent: 8,835,474

Title:	Remedy for overactive bladder comprising acetic acid anilide derivative as the active ingredient
Abstract:	(R)-2-(2-aminothiazol-4-yl)-4'-[2-[(2-hydroxy-2-phenylethyl)amino]ethyl]a- cetic acid anilide or its salt shows a potent bladder relaxation effect in "isolated rat bladder smooth muscle relaxation test", dose-dependently lowers the contraction frequency of rhythmic bladder contractions in "rat rhythmic bladder contraction measurement test" and, moreover, prolongs the urination intervals in "urination functions measurement test on cyclophosphamide-induced overactive bladder model rat". Owing to these effects, the above compound is useful as a remedy for overactive bladder.
Inventor(s):	Takasu; Toshiyuki (Tsukubamirai, JP), Sato; Shuichi (Tsukuba, JP), Ukai; Masashi (Tsukuba, JP), Maruyama; Tatsuya (Tsuchiura, JP), Shibasaki; Masayuki (Tokyo, JP)
Assignee:	Astellas Pharma Inc. (Tokyo, JP)
Filing Date:	May 27, 2011
Application Number:	13/117,638
Claims:	1. A method for treating overactive bladder comprising administering an effective amount of (R)-2-(2-aminothiazol-4-yl)-4'-[2-[(2-hydroxy-2-phenylethyl)amino]ethyl]a- cetic acid anilide or a salt thereof as an active ingredient to a subject in need thereof. 2. The method according to claim 1, wherein said overactive bladder is a result of benign prostatic hyperplasia. 3. The method according to claim 1, wherein said subject has urinary urgency. 4. The method according to claim 1, wherein said subject has urinary incontinence. 5. The method according to claim 1, wherein said subject has pollakiuria. 6. The method according to claim 1, wherein (R)-2-(2-aminothiazol-4-yl)-4'-[2-[(2-hydroxy-2-phenylethyl)amino]ethyl]a- cetic acid anilide or a salt thereof is administered orally. 7. A method for treating overactive bladder comprising administering an effective amount of a free base of (R)-2-(2-aminothiazol-4-yl)-4'-[2-[(2-hydroxy-2-phenylethyl)amino]ethyl]a- cetic acid anilide as an active ingredient to a subject in need thereof. 8. The method according to claim 7, wherein said overactive bladder is a result of benign prostatic hyperplasia. 9. The method according to claim 7, wherein said subject has urinary urgency. 10. The method according to claim 7, wherein said subject has urinary incontinence. 11. The method according to claim 7, wherein said subject has pollakiuria. 12. The method according to claim 7, wherein the free base of (R)-2-(2-aminothiazol-4-yl)-4'-[2-[(2-hydroxy-2-phenylethyl)amino]ethyl]a- cetic acid anilide is administered orally.